Published

Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of Psychedelic Studies
Date: 2026-02-12
Source: OpenAlex
DOI: 10.1556/2054.2026.00485
PubMed: Unavailable

Authors

Matthew Hicks Olivia Hicks Ryan Bradley Heather Zwickey

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Chronic Pain Clinical Trial Randomized Controlled Trial Observational Study Adverse Events Toxicity Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Balancing safety and access in Oregon’s psilocybin services2026-09-01 Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico2026-06-17 Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study2026-02-12

Related papers

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use DisorderClinicalTrials.gov · 2026-08-06 Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress DisorderClinicalTrials.gov · 2026-07-30 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-08-07 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17